Kirkland & Ellis is acting for Hong Kong-listed China Traditional Chinese Medicine Co. Limited (HKSE: 570) in its proposed issuance of new shares to its controlling shareholder and two executive directors, and its share placement to 25 professional and international institutional investors for a total amount of HK$7.2 billion (approx US$930 million). The transaction was announced on 30 March 2015.
The Kirkland team is led by Hong Kong-based corporate partners Frank Sun, Joey Chau and David Yun.
For more information, please click here.
Kirkland & Ellis is also acting for China Traditional Chinese Medicine in its proposed acquisition of a 87.30% stake in Jiangyin Tianjiang Pharmaceutical Co. Ltd., the largest manufacturer of concentrated traditional Chinese medicine granules in China, from eight sellers including, among others, two CICC-affiliated funds, Shanghai-listed Shanghai Jiahua United Co., Ltd. (SSE: 600315) and Shanghai-listed Guangdong Keda Clean Energy Co., Ltd. (SSE: 600499).
For more information about the acquisition, please click here.